

Figure 1




Figure 2




Figure 3

Clinicopathologic features and outcome of 12 consecutive patients with relapsed acute promyelocytic leukemia treated with oral

As <sub>2</sub> O <sub>3</sub>	sex / age	status	previous	induction	treatment	Time from		relapse		Oral As <sub>2</sub> O <sub>3</sub> therapy		Latest	PCR <sup>1</sup>	DFS	Remarks
						last CR	WBC	Hb	Plat	duration additional Rx	result				
1* M / 23	R1	ATRA + Dauno	11 m	15.6	2.1	87	59 d	Ida	CR	Ida		13 m			
	R2	i.v. As <sub>2</sub> O <sub>3</sub> + Ida	10 m	14.0	2.5	25	76 d	ATRA	NR	-	+ (dead)				
2* M / 33	R2	Dauno / i.v. As <sub>2</sub> O <sub>3</sub> + Ida	25 m	13.4	2.1	20	32 d	ATRA	CR	As <sub>2</sub> O <sub>3</sub> + ATRA	- (18 m)	19 m +			
3* F / 13	R2	ATRA + i.v. As <sub>2</sub> O <sub>3</sub>	12 m	8.6	1.2	15	30 d	ATRA	CR	As <sub>2</sub> O <sub>3</sub> + ATRA	- (18 m)	19 m +			
4 M / 54	R1	ATRA + Dauno	100 m	8.5	34.8	81	40 d	Ida	CR	Ida		18 m +			
5* M / 32	R1	ATRA + Dauno + MP	22 m	14.5	2.4	177	33 d	-	CR	Ida		18 m +			
6 F / 32	R1	ATRA + Dauno	12 m	12.2	0.8	84	51 d	-	CR	Ida		18 m +			
7* F / 45	R2	ATRA + Dauno / i.v. As <sub>2</sub> O <sub>3</sub> + Ida	17 m	11.2	1.9	50	37 d	ATRA	CR	As <sub>2</sub> O <sub>3</sub> + ATRA	- (14 m)	17 m +			
8 F / 65	R1	ATRA	16 m	7.2	2.8	141	28 d	-	CR	As <sub>2</sub> O <sub>3</sub> + ATRA	- (12 m)	15 m +	CRF due to DM on CAPD, Ida consolidation omitted due to CRF		
9 F / 18	R2	ATRA + Dauno / i.v. As <sub>2</sub> O <sub>3</sub> + Ida	12 m	10.1	1.9	180	28 d	ATRA	CR	As <sub>2</sub> O <sub>3</sub> + ATRA	- (12 m)	14 m +			
10* F / 18	R1	ATRA + Dauno	12 m	8.2	12.6	54	44 d	Ida	CR	Ida	- (6 m)	9 m +			
11* M / 45	R1	ATRA + Dauno	240 m	4.2	0.6	9	22 d	-	CR	As <sub>2</sub> O <sub>3</sub>	- (3 m)	7 m +	Ida consolidation omitted due to high cumulative doses of anthracycline		
12 F / 40	R1	ATRA + Ara-c	23 m	8.5	6.5	39	28 d	Ida	CR	Ida	- (3 m)	6 m +	CRHD, double valve rep		

\*: pharmacokinetic data of oral  $As_2O_3$  have previously been reported<sup>6</sup>

1: PCR for *PMLRAR4*; +: positive, -: negative. (time from initial diagnosis)

W: male; F: female; CB: complete remission; NR: non-remission; R1: first relapse; R2: second relapse

WBC: white blood cell count; Hb: hemoglobin (g/dL); WBC: white blood cell count ( $\times 10^9/L$ ); Plat: platelet count ( $\times 10^9/L$ ).

DFC: complete blood count; Hb: hemoglobin; HbC: hemoglobin C; months; d: days; DFS: disease free survival

ATRA: all-trans retinoic acid; Dauno: daunorubicin; Ida: idarubicin; Ara-c: cytosine arabinoside

CA: carcinoma; AML: acute myeloid leukemia; CRF: chronic renal failure; DM: diabetes mellitus

CAPPD: continuous ambulatory peritoneal dialysis; CRHD: chronic rheumatic heart disease; rep: replacement